ArticleCureus2025
Posterior Reversible Encephalopathy Syndrome in an Eclamptic Adolescent: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a neurological condition with diverse etiologies, characterized by transient changes in brain imaging and patient behavior. In this case report, a 13-year-old patient in labor developed eclampsia; hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome; and ultimately, PRES. PRES is relatively uncommon in adolescents and was likely triggered by the extreme hypertensive stress experienced by this patient. Prompt identification and treatment with antihypertensive and anti-seizure medications led to a relatively rapid resolution of the patient's postictal, minimally responsive state. Early recognition and management of PRES, particularly in adolescents, are crucial to reducing the risk of long-term complications. Although the long-term outcomes of PRES are not well understood, further research is needed to explore its potential impacts, especially in adolescent populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.